Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged > 65 years
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Hyong | - |
dc.contributor.author | Choi, Jung-Hyun | - |
dc.contributor.author | Park, Sun Hee | - |
dc.contributor.author | Yoo, Jin-Hong | - |
dc.contributor.author | Lee, Dong Gun | - |
dc.contributor.author | Choi, Su-Mi | - |
dc.contributor.author | Kim, Yang Ree | - |
dc.contributor.author | Lee, Mi Suk | - |
dc.contributor.author | Choo, Eun Ju | - |
dc.contributor.author | Choi, Hee Jung | - |
dc.date.accessioned | 2021-09-10T05:46:12Z | - |
dc.date.available | 2021-09-10T05:46:12Z | - |
dc.date.issued | 2021-06-16 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.issn | 1358-8745 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18769 | - |
dc.description.abstract | Background: Seasonal Influenza is still considered associated with seasonal morbidity and hospitalization in the elderly population. The World Health Organization (WHO) recommended seasonal quadrivalent influenza vaccine (QIV) to reduce burden of two currently circulating influenza B lineages. Until 2019 Korean National Immunization Program (NIP) recommended trivalent influenza vaccine (TIV) after ongoing debates on cost effectiveness of QIV for elderly population. Although influenza vaccine only showed modest effect on reducing influenza in elderly, this study aimed to evaluate the immunogenicity and safety of inactivated QIV in healthy participants > 65 years of age. Methods: A total of 274 healthy participants aged > 65 years received a QIV. Seroconversion-based vaccine efficacy of 4 strains of seasonal influenza was assessed 21 days after vaccination and adverse events were monitored until 180 days after vaccination. Results: The percentages of participants seroconverted after vaccination on HI antibody against each strain were 36.5% (99/271) to A/H1N1, 47.6% (129/271) to A/H3N2, 40.6% (110/271) to B Yamagata, and 49.1% (133/271) to B Victoria. The percentages of participants seroprotected after vaccination on HI antibody against each strain were 81.2% (220/271) to A/H1N1, 98.5% (267/271) to A/H3N2, 95.2% (258/271) to B Yamagata, and 93.7% (254/271) to B Victoria. There was no serious adverse event (SAE) related with the study vaccine. Conclusion: The quadrivalent split influenza vaccine is expected to offer seroprotection against influenza A and both influenza B lineages even in the elderly population. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/). | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged > 65 years | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.vaccine.2021.05.001 | - |
dc.identifier.scopusid | 2-s2.0-85105773560 | - |
dc.identifier.wosid | 000659020000011 | - |
dc.identifier.bibliographicCitation | Vaccine, v.39, no.27, pp 3621 - 3625 | - |
dc.citation.title | Vaccine | - |
dc.citation.volume | 39 | - |
dc.citation.number | 27 | - |
dc.citation.startPage | 3621 | - |
dc.citation.endPage | 3625 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordAuthor | Quadrivalent Influenza Vaccine | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Immunogenicity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.